Remote Assessment: The Correct Subtype Matters
An oligodendroglioma diagnosis is special because it is molecularly distinct from other gliomas and, being chemosensitive, directly influences treatment. For this reason, in an international assessment we ask you to share, alongside your MRI, any pathology and molecular results (IDH, 1p/19q) via WhatsApp. In this online opinion, the tumor's features, the suitability of surgery and whether traveling to Turkey is meaningful for your situation are discussed honestly, because the correct molecular diagnosis determines both the treatment plan and realistic expectations.
What Is Oligodendroglioma?
Oligodendroglioma is a diffuse infiltrative brain tumor that develops from oligodendrocytes, the cells that produce the myelin sheathing nerve fibers, and accounts for roughly 5% of all primary intracranial tumors. It is usually located in the white matter of the cerebral hemispheres, most often the frontal lobe, and typically occurs in young-to-middle-aged adults aged 35-50. Because of its cortical location, many patients present with epilepsy (seizures) as the sole symptom for a long period. Having the most favorable prognosis among diffuse gliomas makes it special in terms of recognizing and planning it correctly—which explains why molecular results matter so much in an international assessment.
The Diagnosis Is Made by 1p/19q and IDH
MRI is the principal imaging method; the tumor typically appears as a cortical-subcortical lesion that is hyperintense on T2/FLAIR, and the calcification often seen on CT aids the diagnosis. However, the definitive diagnosis is made only by molecular examination of tissue: under the 2021 WHO classification, demonstration of both an IDH1/IDH2 mutation and 1p/19q co-deletion is mandatory for the diagnosis of oligodendroglioma. Without these tests, oligodendroglioma cannot be diagnosed; IDH-mutant tumors without 1p/19q co-deletion fall into the astrocytoma category. For this reason, surgery (or stereotactic biopsy) is a critical step both for treatment and for an accurate molecular diagnosis. In a patient coming from abroad, the MRI at hand may raise suspicion, but the definitive subtype becomes clear only with tissue.
The Treatment Journey in Turkey and Preserving Function
In the 2021 WHO classification, oligodendroglioma is classified only as grade 2 or 3; there is no grade 4. The first step is the widest safe surgical resection; awake craniotomy and cortical mapping are used for tumors near critical functional (eloquent) areas. If surgery is found appropriate after the remote opinion, the date and estimated length of stay are planned before your arrival. Because of calcification and increased vascularity, the bleeding risk may be somewhat higher than in some gliomas; this is taken into account in surgical planning. After surgery there is usually 24-48 hours of intensive care and a few days in hospital; the extent of resection is assessed with a control MRI, and the pathology-molecular result is provided in writing for continuation treatment in your home country.
Prognosis, Realistic Expectations and Multilingual Communication
Thanks to 1p/19q co-deletion and IDH mutation, oligodendroglioma has the most favorable prognosis among diffuse gliomas and responds to radiotherapy and chemotherapy; for low-grade cases options after surgery include close surveillance, the IDH inhibitor vorasidenib and radiotherapy-chemotherapy when needed, while for grade 3 the standard is radiotherapy combined with chemotherapy (PCV or temozolomide). It is not correct to call it 'benign'; because it is a diffuse tumor, close follow-up is recommended. The risks of surgery (bleeding, infection, a temporary/permanent deficit, edema, seizures) are discussed openly. For a patient coming from across a border, the most important point is that these expectations and the long-term follow-up plan are clearly understood in their own language. We make no guaranteed promises; expectations are shared openly from the start.